240 related articles for article (PubMed ID: 10389914)
1. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin.
Grant SC; Kris MG; Houghton AN; Chapman PB
Clin Cancer Res; 1999 Jun; 5(6):1319-23. PubMed ID: 10389914
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
Giaccone G; Debruyne C; Felip E; Chapman PB; Grant SC; Millward M; Thiberville L; D'addario G; Coens C; Rome LS; Zatloukal P; Masso O; Legrand C
J Clin Oncol; 2005 Oct; 23(28):6854-64. PubMed ID: 16192577
[TBL] [Abstract][Full Text] [Related]
3. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
[TBL] [Abstract][Full Text] [Related]
4. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant.
McCaffery M; Yao TJ; Williams L; Livingston PO; Houghton AN; Chapman PB
Clin Cancer Res; 1996 Apr; 2(4):679-86. PubMed ID: 9816218
[TBL] [Abstract][Full Text] [Related]
5. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB
Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205
[TBL] [Abstract][Full Text] [Related]
6. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.
Chapman PB
Curr Opin Investig Drugs; 2003 Jun; 4(6):710-5. PubMed ID: 12901230
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside.
Chapman PB; Williams L; Salibi N; Hwu WJ; Krown SE; Livingston PO
Vaccine; 2004 Jul; 22(21-22):2904-9. PubMed ID: 15246627
[TBL] [Abstract][Full Text] [Related]
8. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer.
Bottomley A; Debruyne C; Felip E; Millward M; Thiberville L; D'Addario G; Rome L; Zatloukal P; Coens C; Giaccone G
Eur J Cancer; 2008 Oct; 44(15):2178-84. PubMed ID: 18676140
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
[TBL] [Abstract][Full Text] [Related]
10. Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination.
Krug LM; Grant SC; Miller VA; Ng KK; Kris MG
Semin Oncol; 1999 Oct; 26(5 Suppl 15):55-61. PubMed ID: 10566613
[TBL] [Abstract][Full Text] [Related]
11. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
12. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome.
Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E
Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918
[TBL] [Abstract][Full Text] [Related]
13. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
14. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
15. Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer.
Shepherd FA
Semin Oncol; 2001 Apr; 28(2 Suppl 4):30-7. PubMed ID: 11479895
[TBL] [Abstract][Full Text] [Related]
16. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits.
Uyl-de Groot CA; Vermorken JB; Hanna MG; Verboom P; Groot MT; Bonsel GJ; Meijer CJ; Pinedo HM
Vaccine; 2005 Mar; 23(17-18):2379-87. PubMed ID: 15755632
[TBL] [Abstract][Full Text] [Related]
19. Nonspecific adjuvant immunotherapy of lung cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin.
Yasumoto K; Manabe H; Yanagawa E; Nagano N; Ueda H; Hirota N; Ohta M; Nomoto K; Azuma I; Yamamura Y
Cancer Res; 1979 Aug; 39(8):3262-7. PubMed ID: 222448
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
